ts-142
Small moleculeexperimental
Clinical trial activity
16 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Oct 17, 2015 (NCT04169893)
Timeline
Indications
Mechanism of action
- Orexin receptorANTAGONIST
Orexin receptor antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05819710 | Phase 1 | May 15, 2023 | Taisho Pharmaceutical |
| NCT05707897 | Phase 1 | Feb 15, 2023 | Taisho Pharmaceutical |
| NCT05624944 | Phase 1 | Nov 28, 2022 | Taisho Pharmaceutical |
| NCT05461352 | Phase 3 | Oct 11, 2022 | Taisho Pharmaceutical |
| NCT05453136 | Phase 3 | Aug 30, 2022 | Taisho Pharmaceutical |
| NCT04873323 | Phase 1 | Jun 7, 2021 | Taisho Pharmaceutical |
| NCT04814771 | Phase 1 | Apr 19, 2021 | Taisho Pharmaceutical |
| NCT04746105 | Phase 1 | Feb 24, 2021 | Taisho Pharmaceutical |
| NCT04696952 | Phase 1 | Jan 16, 2021 | Taisho Pharmaceutical |
| NCT04557163 | Phase 1 | Oct 13, 2020 | Taisho Pharmaceutical |
| NCT04464239 | Phase 1 | Sep 14, 2020 | Taisho Pharmaceutical |
| NCT04469023 | Phase 2 | Sep 9, 2020 | Taisho Pharmaceutical |
| NCT04087707 | Phase 2 | Sep 17, 2019 | Taisho Pharmaceutical |
| NCT04573725 | Phase 2 | Jul 7, 2017 | Taisho Pharmaceutical |
| NCT04169906 | Phase 1 | Jul 6, 2016 | Taisho Pharmaceutical |
| NCT04169893 | Phase 1 | Oct 17, 2015 | Taisho Pharmaceutical |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Taisho Pharmaceutical | For profit | 16 | 16 | 3 | 2015 |
1 organizations
Page 1 / 1